Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incannex Healthcare Inc. - Common Stock
(NQ:
IXHL
)
1.820
-0.020 (-1.09%)
Streaming Delayed Price
Updated: 3:11 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Incannex Healthcare Inc. - Common Stock
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
May 01, 2024
Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to...
Via
Newsfile
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
Incannex preparing psilocybin therapy FDA IND application
August 24, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley tells Proactive the company is preparing an application to gain key regulatory approval to begin clinical trials in...
Via
TheNewswire.com
Exposures
Product Safety
Incannex full steam ahead towards sleep apnoea trial
August 23, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive after the company received clearance from the US Food and Drug Administration (FDA) to begin...
Via
TheNewswire.com
Topics
Cannabis
Exposures
Cannabis
Product Safety
Incannex thrilled with positive pre-IND meeting for arthritis treatment
July 27, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting...
Via
TheNewswire.com
Exposures
Product Safety
Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial
July 18, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical...
Via
TheNewswire.com
Incannex CEO talks plans to redomicile to US
July 11, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun the process of shifting all outstanding shares to the Nasdaq after making the decision to redomicile...
Via
TheNewswire.com
Incannex appoints principal investigators for pivotal IHL-42X trial
June 19, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X,...
Via
TheNewswire.com
Exposures
Product Safety
Incannex welcomes world-leading psychedelics experts to advisory board
June 01, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) director Peter Widdows tells Proactive the company has appointed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group...
Via
TheNewswire.com
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
May 03, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics...
Via
TheNewswire.com
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
March 03, 2023
Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD Joel Latham sits down with Proactive to talk about the development and manufacturing deal it has struck with pharma giant Catalent to produce...
Via
TheNewswire.com
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
February 28, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients...
Via
TheNewswire.com
Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea: Incannex Healthcare Limited (NASDAQ: IXHL)
May 24, 2022
Via
Get News
Exposures
Product Safety
Advancements for Anxiety, Sleep Apnea, Brain Injury, Lung Inflammation, Rheumatoid Arthritis & Inflammatory Bowel Disease: Incannex Healthcare Limited (NASDAQ: IXHL)
May 05, 2022
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.